Suppr超能文献

相似文献

1
Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs.
Proc Natl Acad Sci U S A. 2013 May 28;110(22):8942-7. doi: 10.1073/pnas.1217206110. Epub 2013 May 14.
9
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Oncogene. 2000 Jul 6;19(29):3309-20. doi: 10.1038/sj.onc.1203650.

引用本文的文献

2
PROTAC Technology as a New Tool for Modern Pharmacotherapy.
Molecules. 2025 May 11;30(10):2123. doi: 10.3390/molecules30102123.
3
The Peptide PROTAC Modality: A New Strategy for Drug Discovery.
MedComm (2020). 2025 Mar 24;6(4):e70133. doi: 10.1002/mco2.70133. eCollection 2025 Apr.
4
Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics.
Chem Rev. 2025 Feb 26;125(4):2120-2183. doi: 10.1021/acs.chemrev.4c00595. Epub 2025 Jan 17.
5
Promising Proteolysis-Targeting Chimera for Mutant p53-R175H.
ACS Omega. 2024 Nov 1;9(45):45138-45146. doi: 10.1021/acsomega.4c06177. eCollection 2024 Nov 12.
6
Methylarginine targeting chimeras for lysosomal degradation of intracellular proteins.
Nat Chem Biol. 2024 Dec;20(12):1566-1576. doi: 10.1038/s41589-024-01741-y. Epub 2024 Oct 16.
7
Targeted Degradation of Protein Kinase A via a Stapled Peptide PROTAC.
ACS Chem Biol. 2024 Sep 20;19(9):1888-1895. doi: 10.1021/acschembio.4c00237. Epub 2024 Aug 13.
8
Recent advancements in targeted protein knockdown technologies-emerging paradigms for targeted therapy.
Explor Target Antitumor Ther. 2023;4(6):1227-1248. doi: 10.37349/etat.2023.00194. Epub 2023 Dec 26.
9
Targeting bacterial degradation machinery as an antibacterial strategy.
Biochem J. 2023 Nov 15;480(21):1719-1731. doi: 10.1042/BCJ20230191.

本文引用的文献

1
SH2 domains recognize contextual peptide sequence information to determine selectivity.
Mol Cell Proteomics. 2010 Nov;9(11):2391-404. doi: 10.1074/mcp.M110.001586. Epub 2010 Jul 13.
2
Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One.
ACS Chem Biol. 2008 Nov 21;3(11):677-692. doi: 10.1021/cb8001792.
3
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
Oncogene. 2008 Dec 4;27(57):7201-11. doi: 10.1038/onc.2008.320. Epub 2008 Sep 15.
4
Proteasome inhibition by fellutamide B induces nerve growth factor synthesis.
Chem Biol. 2008 May;15(5):501-12. doi: 10.1016/j.chembiol.2008.03.020.
5
ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):215-23. doi: 10.1007/s10911-008-9083-7. Epub 2008 May 3.
6
The ERBB3 receptor in cancer and cancer gene therapy.
Cancer Gene Ther. 2008 Jul;15(7):413-48. doi: 10.1038/cgt.2008.15. Epub 2008 Apr 11.
7
RNAi screening for therapeutic targets in human malignancies.
Curr Pharm Biotechnol. 2007 Dec;8(6):337-43. doi: 10.2174/138920107783018426.
8
Molecular genetic approaches for studying the etiology of diabetic nephropathy.
Curr Mol Med. 2005 Aug;5(5):509-25. doi: 10.2174/1566524054553504.
9
Chemical approaches to controlling intracellular protein degradation.
Chembiochem. 2005 Jan;6(1):40-6. doi: 10.1002/cbic.200400274.
10
Chemical genetic control of protein levels: selective in vivo targeted degradation.
J Am Chem Soc. 2004 Mar 31;126(12):3748-54. doi: 10.1021/ja039025z.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验